Please assess the completion status of the following clinical trial:

Trial Title: Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Laboratory-confirmed HIV~* Written informed consent~* Adults 20-59 years of age~Exclusion Criteria:~* Allergies to eggs, thimerosal or gentamicin sulphate~* Life-threatening reaction to previous Flu vaccine~* Bleeding disorder~* Pregnancy~* Receipt of blood or blood products in past 3 months~* Chronic illness~* Previous lab-confirmed H1N12009 infection~* Receipt of any non-study H1N12009 or Seasonal Influenza vaccine for 2009/10

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- One Dose Influenza vaccine (Type: ACTIVE_COMPARATOR): Arepanrix H1N1 Influenza vaccine (one dose)
- Two Doses Influenza vaccine (Type: ACTIVE_COMPARATOR): Arepanrix H1N1 Influenza vaccine (2 doses, 3 weeks apart)

Based on this trial design, predict the completion outcome and termination type (if applicable).